Brain cancer breakthrough? CAR t cells injected directly into fluid around brain in new trial

NCT ID NCT05625594

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new approach to treat central nervous system (CNS) lymphoma by injecting specially engineered immune cells (CAR T cells) directly into the fluid surrounding the brain. The study involves 20 participants and aims to find the safest dose while monitoring side effects and tumor response. If it works, this method could offer a more targeted way to fight cancer in the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-targeting CAR T cells (genetically modified immune cells)
What this could lead to: If successful, this could provide a new treatment option for CNS lymphoma by delivering cancer-fighting cells directly to the brain.
What could go wrong: This is an early phase 1 trial with only 20 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.